Bristol-Myers Squibb’s long-serving chief executive Giovanni Caforio has said he will retire on 1st November after almost eight years in the role and more than two decades
The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of
The first quarter of 2023 saw just £295 million raised by UK-based life sciences and biotech companies, signalling that investor confidence remains low after a disappointi
Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera
Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovat